SCHEMBL12377842

SCHEMBL12377842

Cc1cccc(-c2nn(C)c(=S)o2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.50
RAB9A P51151 7/20 0.50
SMN1; SMN2 Q16637 6/20 0.50
HPGD P15428 6/20 0.50
TSHR P16473 2/20 0.50
MAPT P10636 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALDH1A1 P00352 4/20 0.45
HSD17B10 Q99714 2/20 0.45
TP53 P04637 1/20 0.45
POLB P06746 1/20 0.45
NOTUM Q6P988 1/20 0.45
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 3/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
PPARG P37231 1/20 0.39
NCOA2 Q15596 1/20 0.39
NCOA1 Q15788 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12377820 0.81 NOTUM (0.55) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL20323166 0.80 NOTUM (0.45) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL11674120 0.71 SMN1; SMN2 (0.89) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL12377840 0.70 RAB9A (0.42) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL13882293 0.70 SMN1; SMN2 (0.85) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL16675211 0.68 SMN1; SMN2 (0.82) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL12377829 0.68 GRIN1 (0.47) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL12377825 0.68 GRIN1 (0.47) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL12377823 0.68 NOTUM (0.49) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL12377822 0.68 IL2 (0.49) NPC1RAB9ASMN1; SMN2HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998954-B2 Pyrimidodiazepinone derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-16 US disclosed
US-7998954-B2 Pyrimidodiazepinone derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-16 US disclosed
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD (JP) 2010-07-29 US disclosed
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KCNJ1, KCNJ11, ADRA1D NPC1 1132/4885RAB9A 2645/4885SMN1; SMN2 3525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.